Shattuck Labs presents SL-325 Phase 1 safety and tolerability data
STTK•STTK•STTK•STTK•Shattuck Labs said its completed SL-325 Phase 1 trial showed no serious adverse events and a 3.7% anti-drug antibody rate. The company reported $196.3 million in cash, cash equivalents and short-term investments at September 30, 2026, supporting planned operations into 2029.
Shattuck Labs said its completed Phase 1 trial of SL-325 showed no serious adverse events; the anti-drug antibody rate was 3.7%. Its Phase 2b Crohn’s disease trial is ongoing, with 12-week induction data expected in the first half of 2028.
A Phase 2b trial of SL-325 for hidradenitis suppurativa is expected to start in the fourth quarter of 2026, with 16-week data due in the first half of 2028. Shattuck plans to initiate a Phase 1 trial of SL-846 in the first half of 2027 and expects initial data that year. Cash, cash equivalents and short-term investments totaled $196.3 million at September 30, 2026, supporting planned operations into 2029.
